Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of LY2127399 in Rheumatoid Arthritis
2010-022208-36Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of tabalumab in rheumatoid arthritis (RA) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of patients developing anti-LY2127399 antibodies. Started Nov 2010; status: terminated.
02
Drugs
tabalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-022208-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022208-36.